...
首页> 外文期刊>The Journal of dermatology >Treatment of lipoid proteinosis with acitretin in two patients from two unrelated Chinese families with novel nonsense mutations of the ECM1 gene
【24h】

Treatment of lipoid proteinosis with acitretin in two patients from two unrelated Chinese families with novel nonsense mutations of the ECM1 gene

机译:阿维A治疗两名中国无关家庭中两名患有ECM1基因新无意义突变的类固醇脂蛋白病

获取原文
获取原文并翻译 | 示例
           

摘要

Lipoid proteinosis is a rare recessive genetic disorder caused by loss-of-function mutations to chromosome 1 at 1q21, the extracellular matrix protein 1 (ECM1) gene. Two children with lipoid proteinosis were reported from two unrelated Chinese families, both manifesting with a typical hoarse voice, white acne-like atrophic lesions and scarring on the skin, and beaded papules around the eyelids. The diagnosis had been confirmed by laboratory tests, skin biopsy and laryngoscope examination. Genomic DNA sequencing was performed for both children and their family members. The two children were treated with acitretin for 6 months and followed up for 1 year. Genomic DNA sequencing of the ECM1 gene showed a novel homozygous nonsense mutation of C1522>T (p. R508X) at exon 10 in one patient, and a novel compound heterozygote for a nonsense/frame-shift combination of mutations of R281X/1596delG at exons 7 and 10 in the other patient. The symptom of hoarse voice was improved by 6-month treatment with acitretin, while there was no improvement in the skin lesions. These results demonstrated that acitretin treatment may have efficacy for some of patients with lipoid proteinosis, with superior effect on laryngeal symptoms than skin lesions. However, the conclusive therapeutic effect and underlying mechanisms remain to be further investigated.
机译:类脂蛋白病是一种罕见的隐性遗传病,由1q21号染色体1的功能丧失突变(细胞外基质蛋白1(ECM1)基因)引起。据报道,来自两个不相关的中国家庭的两名儿童类脂蛋白沉着症,均表现为典型的声音嘶哑,白色痤疮样萎缩性病变和皮肤疤痕,以及眼睑周围的珠状丘疹。诊断已通过实验室检查,皮肤活检和喉镜检查得到证实。对儿童及其家庭成员均进行了基因组DNA测序。这两个孩子用阿维A治疗了6个月,并随访了1年。 ECM1基因的基因组DNA测序显示一名患者在外显子10处出现新的C1522> T纯合性无义突变(p。R508X),在外显子上无意义/移码组合了R281X / 1596delG突变的新型复合杂合子另一个病人是7和10。阿维A 6个月治疗改善了声音嘶哑的症状,而皮肤病变没有改善。这些结果表明,阿维A治疗可能对某些类脂蛋白沉着病患者有效,对喉部症状的疗效优于皮肤病变。然而,最终的治疗效果和潜在机制仍有待进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号